BrainAurora Medical Technology (HKG:6681) launched its HK$583.2 million initial public offering in Hong Kong on Monday.
The digital diagnostics and therapies provider is offering 181,112,000 shares at HK$3.22 apiece.
BrainAurora secured four cornerstone investors, including Tasly Pharmaceuticals (SHA:600535), which committed to subscribe to $48.5 million worth of IPO shares.
The issuer expects to disclose the allocations on Jan. 7. It will start trading on the Hong Kong bourse on Jan. 8, according to a Monday filing.
Deal proceeds will be used for research and development, clinical trials, technology upgrades, new cognitive centers, and working capital.
CICC, SPDB International, CMBC International, Fosun International, GF Securities, and several others are the joint book-runners of the IPO.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。